Bayer and Orion expand development program for NUBEQA® (darolutamide) in prostrate cancer
Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the androgen receptor inhibitor (ARi) in combination with standard androgen deprivation therapy (ADT) Start of patient enrollment expected by the end of Q1 2021 Study adds to the